Personalized medicine for HER2 positive breast cancer

被引：0
|
作者：
Tamura, Kenji [1 ]
机构：
[1] Natl Canc Ctr Hosp, Dept Breast & Med Oncol, Chuo, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SY-15-2
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Personalized Medicine in HER2-positive breast cancer
    Tsurutani, Junji
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [2] Personalized medicine for HER2-positive breast cancer
    Wang, Zhixiang
    [J]. BREAST CANCER MANAGEMENT, 2015, 4 (05) : 237 - 240
  • [3] HER2 positive breast cancer
    Gianni, Luca
    Bianchini, Giampaolo
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [4] IMMUNOTHERAPY FOR HER2 POSITIVE BREAST CANCER
    Vaidya, T. R.
    Ait-Oudhia, S.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S20 - S20
  • [5] Her2 positive breast cancer: practices
    Campone, Mario
    Berton-Rigaud, Dominique
    Bourbouloux, Emmanuelle
    Sophie, Sadot
    Zanetti, Alain
    Frenel, Jean-Sebastien
    [J]. BULLETIN DU CANCER, 2011, 98 (02) : 154 - 163
  • [6] Delayed breast cancer surgery in HER2 positive breast cancer
    Hur, Ho
    Le, Amy
    Chang, Helena R.
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [7] HER2 status in breast cancer patients: A comparison between borderline positive HER2 and strongly positive HER2 tumors
    Huszno, J.
    Nowara, E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S137 - S137
  • [8] Delayed chemotherapy in HER2 positive breast cancer
    Hur, Ho
    Le, Amy
    Chang, Helena R.
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [9] HER2 POSITIVE BREAST CANCER - BIOLOGY AND RESISTANCE
    Penault-Llorca, Frederique
    [J]. BREAST, 2019, 48 : S31 - S31
  • [10] Treatment of HER2 positive breast cancer patients
    Matos, Erika
    [J]. ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2012, 81 (03): : 236 - 245
12345